EU - ERDERA Rare disease clinical trials

Mer information

Observe that the deadline posted above is the deadline for the mandatory Expression of Interest.

Aim: To address key challenges in rare disease clinical trials, where patient populations are often small and geographically dispersed. By fostering multinational collaboration, the call seeks to enable more efficient, inclusive, and impactful research.

While all eligible rare diseases are welcome, the call particularly encourages proposals in pediatric rare diseases, rapidly progressive rare diseases, and rare diseases with no approved therapeutic options or substantial residual unmet need.

Pre proposal: ERDERA Clinical Trial Call 2026: pre‑announcement and key dates - ERDERA

Call opens: 1st of July 2026 Clinical Trial Call 2026 - ERDERA. The first deadline in the multi-stage application process is for the Expression of Interest, 10 September.

Information webinar: 6 July 2026, 15:00–17:00 CEST. Information and registration.

Who can apply: Eligible organisations include: Universities, higher education institutions and research institutes, Hospitals and clinical centres, Non‑profit research organisations and foundations, Patient Advocacy Organisations (PAOs), SMEs (subject to specific funding provisions applicable under the call)

Each consortium must designate: a Clinical Trial Sponsor, a Coordinating Investigator, at least one patient partner represented by a PAO or other organised patient group, access to a qualified multinational Clinical Trial Management Organisation (CTMO)

Eligible interventions include: Small molecules, including repurposed drugs, Advanced Therapy Medicinal Products (ATMPs) (provided the manufacturing process has been developed and validated under GMP conditions appropriate for Phase I/II use), Biologics and New Biological Entities (NBEs), Repurposed biologics

In this call no parallel application is needed to Vinnova or Vetenskapsrådet.